Homoharringtonine exhibits senotherapeutic activity that mitigates diet- and age-associated obesity and insulin resistance and extends lifespan in mice - PubMed
5 hours ago
- #metabolic disease
- #longevity
- #senotherapy
- Homoharringtonine (HHT), an FDA-approved anti-leukemic drug, demonstrates senotherapeutic activity by targeting senescent cells in white adipose tissue (WAT).
- HHT treatment mitigates diet- and age-associated obesity and insulin resistance in male mice by improving WAT function and reducing inflammation.
- Mechanistically, HHT's senotherapeutic effects are mediated through direct interaction with heat shock protein HSPA5.
- The treatment also attenuates age-associated phenotypes in human adipose tissue and extends lifespan in progeroid and aged mice.
- HHT is identified through a drug-repositioning strategy involving 2,150 clinically applied compounds, showing minimal cytotoxicity to non-senescent cells.